31 May 2016 - The subcutaneous formulation of MabThera saves time and eases treatment burden compared with the intravenous form.

Roche announced today that the European Commission has approved the subcutaneous formulation of MabThera (rituximab) for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL). The approved dose for CLL is 1,600 mg. Following the approval of MabThera SC (1,400 mg) for common forms of non-Hodgkin lymphoma in March 2014, this is the second European approval for the subcutaneous formulation.

For more details, go to: http://www.roche.com/media/store/releases/med-cor-2016-05-31.htm